Indivior (NASDAQ:INDV) Lowered to Hold Rating by Zacks Research

Indivior (NASDAQ:INDV) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Barclays initiated coverage on Indivior in a research note on Thursday, June 18th. They issued an “overweight” rating and a $46.00 target price on the stock. Weiss Ratings raised Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.29.

Indivior Stock Performance

Shares of INDV stock opened at $41.03 on Monday. The firm’s 50 day moving average price is $37.40 and its two-hundred day moving average price is $34.75. Indivior has a 52-week low of $14.52 and a 52-week high of $42.81. The stock has a market cap of $5.00 billion, a PE ratio of 21.04 and a beta of 0.88.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The company had revenue of $317.00 million for the quarter. As a group, sell-side analysts predict that Indivior will post 4.05 earnings per share for the current fiscal year.

Insider Activity at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This represents a 11.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Salomon & Ludwin LLC bought a new stake in shares of Indivior in the fourth quarter worth about $30,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares in the last quarter. Quarry LP acquired a new position in shares of Indivior in the 3rd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares during the period. Finally, GAMMA Investing LLC increased its stake in Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares in the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.